Serum Survivin status in patients with systemic Lupus erythematous and its relation with disease activity

Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder that increased rate of apoptosis play a important pathogenic role in SLE and whereas Survivin has anti-apoptotic function this study aimed to evaluate the serum survivin in SLE patients in comparison with healthy controls and to investigate the serum survivin as a potential biomarker in predicting SLE clinical features. Methods: In a cross-sectional study, 62 SLE patients according to the Systemic Lupus International Collaborating Clinics (SLICC) classification and 92 age- and sex-matched healthy controls were enrolled. Complete history taking, detailed physical examination, and laboratory tests was performed. Disease activity was assessed using the systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K). Serum surviving was measured using a kit. Results: Serum survivin level in SLE patients was significantly lower than healthy controls (P< 0.05). Serum survivin levels in active SLE patients, inactive SLE patients and healthy controls were 92.6 (41-130), 114.5 (41-632.5) and 120.4 (9-2992.5) pg/mL, respectively.Serum surviving levels in active SLE patients were significantly lower than inactive SLE group, the difference did not reach to significant level. Moreover, no significant association was noticed between demographic and clinical characteristics of patients with serum survivin levels.